The role of B cells in tumor immunosurveillance has also been described, where higher densities of tumor-infiltrating B cells (TIL-B) positively correlated with improved clinical outcomes in HER2+ BC and TNBC (HR 0.34; 95% CI, 0.12 to 0.95, p = 0.03) [20]. Here, ERBB2 is linked to breast cancer.